These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22621866)

  • 1. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
    Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
    Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.
    Kosinski JR; Hubert J; Carrington PE; Chicchi GG; Mu J; Miller C; Cao J; Bianchi E; Pessi A; Sinharoy R; Marsh DJ; Pocai A
    Obesity (Silver Spring); 2012 Aug; 20(8):1566-71. PubMed ID: 22421924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle.
    ThanThan S; Saito T; Yannaing S; Zhao H; Nakashima K; Kuwayama H
    Domest Anim Endocrinol; 2012 Apr; 42(3):155-64. PubMed ID: 22154917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPP-IV-resistant, long-acting oxyntomodulin derivatives.
    Santoprete A; Capitò E; Carrington PE; Pocai A; Finotto M; Langella A; Ingallinella P; Zytko K; Bufali S; Cianetti S; Veneziano M; Bonelli F; Zhu L; Monteagudo E; Marsh DJ; Sinharoy R; Bianchi E; Pessi A
    J Pept Sci; 2011 Apr; 17(4):270-80. PubMed ID: 21294225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
    Maida A; Lovshin JA; Baggio LL; Drucker DJ
    Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
    Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
    Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.
    ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Yannaing S; Kuwayama H
    Domest Anim Endocrinol; 2013 Feb; 44(2):70-80. PubMed ID: 23122871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet.
    Parlevliet ET; Heijboer AC; Schröder-van der Elst JP; Havekes LM; Romijn JA; Pijl H; Corssmit EP
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E142-7. PubMed ID: 17971509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.
    Bianchi E; Carrington PE; Ingallinella P; Finotto M; Santoprete A; Petrov A; Eiermann G; Kosinski J; Marsh DJ; Pocai A; SinhaRoy R; Pessi A
    Bioorg Med Chem; 2013 Nov; 21(22):7064-73. PubMed ID: 24094437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
    Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
    J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling oxyntomodulin, GLP1's enigmatic brother.
    Pocai A
    J Endocrinol; 2012 Dec; 215(3):335-46. PubMed ID: 23019069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxyntomodulin reduces expression of glucagon-like peptide 1 receptor in the brainstem of chickens.
    Moghaddam AG; Yaghoobi MM; Jonaidi H; Mahani MT; Sepehri H
    J Anim Physiol Anim Nutr (Berl); 2010 Aug; 94(4):422-8. PubMed ID: 19663977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.
    ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Naing SW; Kuwayama H
    Domest Anim Endocrinol; 2017 Apr; 59():30-36. PubMed ID: 27888738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action and therapeutic potential of oxyntomodulin.
    Pocai A
    Mol Metab; 2014 Jun; 3(3):241-51. PubMed ID: 24749050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
    Bhat VK; Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.
    Willard FS; Wootten D; Showalter AD; Savage EE; Ficorilli J; Farb TB; Bokvist K; Alsina-Fernandez J; Furness SG; Christopoulos A; Sexton PM; Sloop KW
    Mol Pharmacol; 2012 Dec; 82(6):1066-73. PubMed ID: 22930710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.
    Zhang X; Cai Y; Yao Z; Chi H; Li Y; Shi J; Zhou Z; Sun L
    Peptides; 2023 Mar; 161():170948. PubMed ID: 36646385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
    Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2010 Dec; 80(11):1727-35. PubMed ID: 20735990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.